Gastrointestinal Cancer News

Researchers at The University of Texas at Austin have developed a handheld device, known as the MasSpec Pen, designed to distinguish between cancerous and healthy tissue within seconds while in the operating room, according to a press release.

Two novel blood assays demonstrated efficacy in detecting various cancer types at different disease stages, according to results of two studies presented at ASCO Breakthrough in Bangkok.

Adding panitumumab to FOLFOXIRI chemotherapy improved rates of overall response and secondary resection of metastases among patients with RAS wild-type metastatic colorectal cancer, according to results of the randomized phase 2 VOLFI trial published in Journal of Clinical Oncology.

The FDA granted the combination of nivolumab and ipilimumab priority review and breakthrough therapy designation for the treatment of patients with advanced hepatocellular carcinoma previously treated with sorafenib, according to a company-issued press release.

A randomized phase 3 trial designed to evaluate avelumab as first-line maintenance therapy for patients with unresectable, locally advanced or metastatic HER2-ngative gastric or gastroesophageal junction cancer failed to meet its primary endpoints.

NATIONAL HARBOR, Md. — An investigational bispecific T-cell engager appeared safe and demonstrated some clinical activity among patients with HER2-positive solid tumors, according to phase 1 dose-escalation study data presented at Society for Immunotherapy of Cancer Annual Meeting.

NATIONAL HARBOR, Md. — An investigational anti-CD73 antibody appeared safe and demonstrated promising antitumor activity among patients with advanced cancers, according to phase 1/1b trial data presented at Society for Immunotherapy of Cancer Annual Meeting.

Association of Community Cancer Centers presented its David King Community Clinical Scientist Award to Paul D. Hansen, MD, FACS.

Hyperbaric oxygen therapy safely relieved symptoms of late radiation cystitis among patients who received radiotherapy for cancer in the pelvic region, according to results of the randomized phase 2/phase 3 RICH-ART trial published in The Lancet Oncology.

Trifluridine and tipiracil significantly extended PFS and OS compared with placebo among patients with previously treated metastatic gastric or gastroesophageal junction cancer, according to results of a subgroup analysis of the randomized phase 3 TAS-102 Gastric Study.